Biochemical Amenability in Fabry Patients Under Chaperone Therapy-How and When to Test? [0.03%]
酶替代治疗法患者的生化指标评估——何时及如何进行？
Malte Lenders,Elise Raphaela Menke,Eva Brand
Malte Lenders
Aim: Current recommendations for Fabry disease include α-galactosidase A (AGAL) activity measurements to assess the biochemical response in migalastat-treated patients. Owing to contradictory data from laboratories, we a...
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab [0.03%]
介绍生物类似药的概念进入神经病学：第一种纳利珠单抗生物类似药的证据总括
Krzysztof Selmaj,Karsten Roth,Josef Höfler et al.
Krzysztof Selmaj et al.
A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired. Biosimilar natalizumab (PB006 [biosim-NTZ...
Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study [0.03%]
源自参照药物阿达木单抗或另一款阿达木单抗类似药的患者转换至CT-P17后的满意度及体验：真实世界YU-MATTER研究结果
Guillaume Bouguen,Laure Gossec,Vered Abitbol et al.
Guillaume Bouguen et al.
Background and objectives: Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs can ...
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects [0.03%]
尼伏单抗类似药LY01015的药代动力学、安全性和免疫原性：一项在中国健康男性受试者中开展的随机、双盲、平行对照I期临床试验
Wei Wang,Shengnan Zhang,Changlin Dou et al.
Wei Wang et al.
Background: Nivolumab (Opdivo®) is the first anti-PD-1 antibody approved in the world. LY01015 is a potential biosimilar of nivolumab. Objectives: ...
Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept [0.03%]
肺动脉高压和TGF-β超家族信号通路：重点关注索他雷塞
Benjamin Stump,Aaron B Waxman
Benjamin Stump
Pulmonary arterial hypertension (PAH) is a rare and progressive disease that continues to remain highly morbid despite multiple advances in medical therapies. There remains a persistent and desperate need to identify novel methods of treati...
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure [0.03%]
从临床前评估到获批：查哥宁病毒疫苗IXCHIQ和PXVX0317研发进展综述
Whitney C Weber,Daniel N Streblow,Lark L Coffey
Whitney C Weber
Chikungunya virus is an emerging mosquito-borne alphavirus that causes febrile illness and arthritic disease. Chikungunya virus is endemic in 110 countries and the World Health Organization estimates that it has caused more than 2 million c...
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems [0.03%]
基因底物减少疗法治疗溶酶体贮积病的系统评价：机遇、挑战及递送体系
Marina Beraza-Millor,Julen Rodríguez-Castejón,Ana Del Pozo-Rodríguez et al.
Marina Beraza-Millor et al.
Background: Genetic substrate reduction therapy (gSRT), which involves the use of nucleic acids to downregulate the genes involved in the biosynthesis of storage substances, has been investigated in the treatment of lysos...
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond [0.03%]
黏多糖贮积症Ⅱ型的神经学治疗靶点：从酶替代疗法到更广泛的治疗手段
Alessandra Zanetti,Rosella Tomanin
Alessandra Zanetti
Mucopolysaccharidosis type II (MPS II) is a rare, pediatric, neurometabolic disorder due to the lack of activity of the lysosomal hydrolase iduronate 2-sulfatase (IDS), normally degrading heparan sulfate and dermatan sulfate within cell lys...
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab [0.03%]
致：关于托珠单抗生物类似物BAT1806/BIIB800与参照药托珠单抗的理化和功能相似性验证的补充
Yujie Liu,Jianhua Xie,Zhuxiang Li et al.
Yujie Liu et al.
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study [0.03%]
维持治疗目标应影响炎症性肠病英夫利西治疗方案的选择：药代动力学模拟研究
Ashish Srinivasan,Daniel van Langenberg,Peter De Cruz et al.
Ashish Srinivasan et al.
Background: The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic infliximab trough levels remains uncertain, as does whether post-intensification trough and treat...